(Q44213569)

30 November 2017

title

Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial (English)

1 reference

30 November 2017

main subject

phase III clinical trial

0 references

1 reference

1 reference

Jolie Ringash

1

0 references

John Zalcberg

6

object named as

John R Zalcberg

1 reference

30 November 2017

Heather-Jane Au

2

1 reference

30 November 2017

Lillian L Siu

3

1 reference

30 November 2017

Jeremy D Shapiro

4

1 reference

30 November 2017

Derek J Jonker

5

1 reference

30 November 2017

Malcolm J Moore

7

1 reference

30 November 2017

Andrew Strickland

8

1 reference

30 November 2017

Rami Kotb

9

1 reference

30 November 2017

Mark Jeffery

10

1 reference

30 November 2017

Thierry Alcindor

11

1 reference

30 November 2017

Siobhan Ng

12

1 reference

30 November 2017

Muhammad Salim

13

1 reference

30 November 2017

Sabe Sabesan

14

1 reference

30 November 2017

Jay C Easaw

15

1 reference

30 November 2017

Jenny Shannon

16

1 reference

30 November 2017

Fabyolla El-Tahche

17

1 reference

30 November 2017

Ian Walters

18

1 reference

30 November 2017

Dongsheng Tu

19

1 reference

30 November 2017

Christopher J O'Callaghan

20

1 reference

30 November 2017

NCIC Clinical Trials Group

21

1 reference

30 November 2017

Australasian Gastrointestinal Trials Group

22

1 reference

30 November 2017

language of work or name

English

0 references

publication date

11 October 2013

1 reference

30 November 2017

1 reference

30 November 2017

volume

120

1 reference

30 November 2017

issue

2

1 reference

30 November 2017

page(s)

181-189

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28410

30 November 2017

1 reference

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28410

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28410

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28410

Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28410

Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28410

Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28410

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28410

Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28410

Completion rates in health-related quality-of-life assessment: approach of the National Cancer Institute of Canada Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28410

Toward patient-centered drug development in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28410

A sharper Bonferroni procedure for multiple tests of significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28410

Interpreting the significance of changes in health-related quality-of-life scores.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28410

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.28410

1 reference

30 November 2017

1 reference